239 results about "Bleomycin" patented technology

The invention discloses an application of MSC (mesenchymal stem cell) exosomes in preparation of a pharmaceutic preparation for treating PF (pulmonary fibrosis). The MSC exosomes are adopted to treat PF of a mouse, the survival rate of the mouse can be remarkably increased, the PF pulmonary lesions caused by BLM (bleomycin) are relieved, the mouse lung tissue pathological score is reduced, and accordingly, the MSC exosomes have wide application prospect in the aspect of preparation of the pharmaceutic preparation for treating PF.

The invention discloses an application of umbilical cord mesenchymal stem cells in preparation of a pharmaceutical preparation for treating the PF (pulmonary fibrosis). When FN-gamma pretreated mesenchymal stem cells are adopted to treat PF of mice, the survival rate of the mice can be increased obviously, BLM (bleomycin) induced PF pulmonary lesion can be relieved, the pulmonary histopathologic score of the mice can be reduced obviously, and the umbilical cord mesenchymal stem cells have broad application prospect in preparation of medicines for treating the PF.

Alkanoyl L-carnitines of the formula:where R is hydrogen or a C2-8 alkanoyl group and X- is an anion of a pharmaceutically acceptable salt, are used in conjunction with anticancer agents such as taxol or bleomycin to improve the therapeutic index and reduce side effects typical of anticancer chemotherapy.

During lung injury, p53 expression increases, inducing plasminogen activator inhibitor-1 (PAI-1) while inhibiting expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR), resulting in apoptosis of lung epithelial cells (LECs). In the bleomycin lung injury model, p53 and PAI-1 are induced while uPA and uPAR are inhibited. A 20 residue peptide DGIWKASFTTFTVTKYWFYR termed PP-1 (the Cav-1 scaffolding domain) or peptide NYHYLESSMTALYTLGH, termed PP-2, protected LECs from bleomycin-induced apoptosis in vitro and in vivo and prevented subsequent pulmonary fibrosis by attenuating lung epitheilial damage. Pharmaceutical compositions, peptide multimers and deliverable polypeptides comprising the above peptides are dislcosed. The peptides and functional variants, peptide multimers, cell-targeted polyepeptides and pharmaceutical compositions are used in methods for inhibiting apoptosis of injured or damaged lung epithelial cells and for treating acute lung injury and consequent pulmonary fibrosis.

The invention relates to an application of flavonoid quercetin in inhibition of skin scar formation and skin fibration. The application verifies that quercetin has no toxicity to fibroblast, human dermal fibroblast I / III-type collagen mRNA expression and protein synthesis can be inhibited by inhibiting a TGF beta1 signal pathway in cells, fibroblast can be inhibited to myofibroblast differentiation, so that skin scar formation or dermal collagen deposition (fibration) can be inhibited, Animal in-vitro experiment confirms that quercetin is effected on mice skin, bleomycin-induced mice skin fibration and tension force-induced mice skin scar formation can be inhibited. Because that quercetin has the characteristics of small molecular weight, high lipid solubility and good transdermal absorption capability, the molecules can be used for preparing the medicine for resisting skin scar formation and skin fibration, and have wide application prospect in medical, shaping and cosmetic fields.

The invention discloses a schizochytrium sp. genetic engineering strain overexpressing a squalene synthetase gene, as well as a construction method and application of the schizochytrium sp. genetic engineering strain. Schizochytrium sp. ATCC1381 is adopted as an original strain, an overexpression vector is constructed in escherichia coli through the means of genetic engineering, bleomycin is selected as a screening resistance gene, the highly conserved sequence 18S rRNA of eucaryon is used as a homologous arm, a linear overexpressed fragment is electro-transformed into the schizochytrium sp toobtain a genetic engineering strain with high yield of squalene, and a theoretical basis is laid for microbial produced squalene and product industrialization.

The invention belongs to the traditional Chinese medicine field and relates to the preparation of effective parts of astragalus mongholicus and hedysarum polybotrys and selection thereof for pulmonary fibrosis model intervention so as to obtain further study on the effective parts having the optimal curative effect. An interstitial pulmonary fibrosis model of rats is established through modeling; and compared with the normal rats, the rats having interstitial pulmonary fibrosis have obvious difference and pathologic change typical cases in various related detection indexes and pathologic changes. The various effective parts of astragalus mongholicus and hedysarum polybotrys are capable of suppressing various related indexes of the interstitial pulmonary fibrosis model of rats induced by bleomycin and preventing the development of interstitial pulmonary fibrosis, wherein low and medium dose groups of hedysarum polybotrys flavone have the optimal effect. The degree of the effect of the effective parts of astragalus mongholicus and hedysarum polybotrys on stopping the progress of interstitial pulmonary fibrosis is related to appropriate concentrations of equivalent dugs. Through comprehensive assessment, the hedysarum polybotrys flavone is better in influence on the lung function, HA, LN, HYP and the like of the rats having interstitial pulmonary fibrosis than other effective parts.

The invention discloses a noninvasive fabricating method for a pulmonary fibrosis animal model. The method comprises the steps: the method that the bacterium solution dropping is poured inside a lower trachea through an endoscope is adopted, and a nasal zero degree 4 # hard-type endoscope, a xenon lamp cold light source and a Panasonic KS-822 video monitoring system are utilized; a rat is placed in a dryer with 26 cm diameter, and the ether anesthesia is carried out on the rat, the 200 microlitre of the medicine bleomycin is ejected inside the trachea, the medicine is fully flowed into the bronchus along with the airflow when inhaling air, elastic fixings clamped on the four limbs of the rat are removed, the rat is placed into a rat cage to wait for the anabiosis, the anabiosis period ranges from 30 sec to 60 sec, and the rat is placed into a constant temperature animal house for feeding; the activity, the feeding and the spirit conditions of the inoculated rat are observed every day, and the corresponding data is recorded.

The invention discloses application of obaculactone in preparation of drugs for treating pulmonary fibrosis, chronic pneumonia and chronic bronchitis and a chronic obstructive pulmonary disease or asthma, and further discloses the related drugs. Obaculactone can effectively and dose-dependently improve the bleomycin-induced mouse pulmonary fibrosis damage and the inflammation symptoms generated in the pathogenic process of the mouse pulmonary fibrosis damage through oral administration. Detection on collagen synthesis shows that obaculactone can dose-dependently regulate down generation of alpha-SMA and collagen, and the effect is based on inhibition of obaculactone on a TGF-beta signal channel in the mouse pulmonary fibrosis tissue. The results show that obaculactone can be applied to multiple inflammation-mediated chronic lung diseases including the pulmonary fibrosis, the chronic pneumonia, silicosis, the chronic bronchitis, the chronic obstructive pulmonary disease and the asthma.

The invention provides application of pazopanib hydrochloride to preparing medicines for treating pulmonary fibrosis diseases, and further provides a medicine composition. The medicine composition contains the pazopanib hydrochloride, excipients and pharmaceutically acceptable salt, ester and hydrates of the pazopanib hydrochloride or compositions of the salt, the ester and the hydrates. The application and the medicine composition have the advantages that excellent effects can be realized by the pazopanib hydrochloride for pulmonary fibrosis, adverse reaction can be prevented, bleomycin-induced pulmonary fibrosis in mice can be relieved, and the medicine composition has an excellent application prospect for treating, relieving and improving the pulmonary fibrosis diseases.

The invention relates to a temperature-controlled sustained-release injection containing an anti-cancer drug, which consists of the anti-cancer drug and an amphiphilic block copolymer hydrogel and has the temperature-sensitive gelatinization feature, the temperature-controlled sustained-release injection is flowable liquid in the environment that is lower than the body temperature and can be automatically converted to the water-insoluble gel that can not flow and be biodegradable for absorption in an endotherm, thus allowing the drug to have the local sustained release in a tumor and maintain the effective drug concentration for a plurality of weeks to a plurality of months; the temperature-controlled sustained-release injection can be injected in the tumor or the tumor periphery or be arranged in the postoperative tumor cavity, thus significantly reducing the systemic reaction of the drug, strengthening the treatment effects of chemotherapy, radiotherapy and other non-surgical therapies, and being used for the treatment of the tumors in different stages. The anti-cancer drug can be vincristine, vinorelbine, navelbine, vindesine, vinleurosine, vinrosidine, cephalotaxine, bleomycin, daunomycin, aclarubicin, epirubicin, idarubicin, pirarubicin, valrubicin, mitomycin C, actinomycin D, losoxantrone, mitoxantrone, mitozolomide, temozolomide and so on.

The invention relates to medicinal application of microcystic toxins-LR, in particular to application of the microcystic toxins-LR in preparation of medicines for preventing and treating pulmonary fibrosis, belonging to the technical field of medicines. The microcystic toxins-LR is proved to be capable of improving the state of pulmonary fibrosis caused by bleomycin. The microcystic toxins-LR can inhibit the mRNA expression rise, caused by the bleomycin, of pulmonary fibrosis-related molecules such as transforming growth factor (TGF)-beta, tumor necrosis factor (TNF)-alpha, IL-1beta, IL-6, NF-kB and ET-1. The microcystic toxins-LR can inhibit the mRNA expression rise, caused by the bleomycin, of lung tissue vascular endothelial growth factor (VEGF). The microcystic toxins-LR interferes and relieves rat pulmonary fibrosis, induced by the bleomycin, by using ways such as a TGF-beta / Smad pathway and angiogenesis inhibition. A new way is provided for preparing the medicines for preventing and / or treating the pulmonary fibrosis disease.